- Report
- August 2024
- 148 Pages
Global
From €2878EUR$2,999USD£2,398GBP
- Report
- May 2024
- 138 Pages
Global
From €6236EUR$6,499USD£5,197GBP
- Report
- May 2024
- 138 Pages
Global
From €6236EUR$6,499USD£5,197GBP
- Report
- May 2024
- 184 Pages
Global
From €4318EUR$4,500USD£3,598GBP
- Clinical Trials
- December 2024
- 240 Pages
Global
From €2879EUR$3,000USD£2,399GBP
- Report
- July 2024
- 150 Pages
Global
From €3598EUR$3,750USD£2,999GBP
- Report
- June 2024
- 200 Pages
Global
From €7628EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7628EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7628EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7628EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7628EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7628EUR$7,950USD£6,357GBP
- Clinical Trials
- June 2024
- 60 Pages
Global
From €1439EUR$1,500USD£1,199GBP
- Clinical Trials
- June 2024
- 240 Pages
Global
From €2879EUR$3,000USD£2,399GBP
- Report
- June 2024
- 200 Pages
Global
From €7628EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7628EUR$7,950USD£6,357GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1919EUR$2,000USD£1,599GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1919EUR$2,000USD£1,599GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2879EUR$3,000USD£2,399GBP
- Report
- January 2025
- 250 Pages
Global
From €4797EUR$4,999USD£3,997GBP

The Prostate Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it can vary depending on the stage and severity of the disease. Common treatments include hormone therapy, chemotherapy, and radiation therapy.
The Prostate Cancer Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Astellas Pharma, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are constantly researching and developing new drugs to treat prostate cancer, as well as improving existing treatments. Show Less Read more